GELNIQUE 3%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GELNIQUE 3% (GELNIQUE 3%).
Oxybutynin is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3 subtypes), primarily M3 receptors, leading to relaxation of detrusor smooth muscle and inhibition of involuntary bladder contractions.
| Metabolism | Primarily metabolized by cytochrome P450 enzymes, specifically CYP3A4, to active and inactive metabolites (e.g., desethyloxybutynin). |
| Excretion | Renal: 70% as unchanged drug; fecal: 20% as metabolites; biliary: 10% |
| Half-life | Terminal half-life: 7.5 hours (range 5-10 h); clinically, steady-state achieved in 2 days |
| Protein binding | 97% bound to alpha-1-acid glycoprotein and albumin |
| Volume of Distribution | Vd: 2.9 L/kg (range 2.0-4.0), indicating extensive tissue distribution |
| Bioavailability | Topical: 18% (range 10-30%) relative to intravenous dose |
| Onset of Action | Topical: 2-4 hours for first measurable anticholinergic effect; maximal effect by 8-12 weeks |
| Duration of Action | Duration: 24 hours with once-daily application; clinical effect maintained with regular use |
| Molecular Weight | 357.49 |
Apply 1 gram (4 metered actuations) of gel topically to dry intact skin on abdomen, upper thighs, or upper arms once daily.
| Dosage form | GEL, METERED |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²); use caution. |
| Liver impairment | No specific dose adjustment; contraindicated in Child-Pugh Class C (severe hepatic impairment). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; monitor for anticholinergic effects and cognitive impairment in elderly patients. |
| 1st trimester | Oxybutynin is Pregnancy Category B. No adequate studies in pregnant women; animal studies have not demonstrated risk. Use only if clearly needed. |
| 2nd trimester | Same as first trimester. |
| 3rd trimester | Same as first trimester. |
Clinical note
Comprehensive clinical and safety monograph for GELNIQUE 3% (GELNIQUE 3%).
| Placental transfer | Oxybutynin crosses the placenta in animal studies; human data limited. Molecular weight and lipophilicity suggest potential transfer. |
| Breastfeeding | Oxybutynin is excreted into breast milk in small amounts. No adverse effects reported in nursing infants. Use with caution in lactating women, especially if the infant has compromised renal function or is premature. |
| Lactation Rating |
■ FDA Black Box Warning
Not applicable (no black box warning for oxybutynin topical gel).
| Serious Effects |
Urinary retentionGastric retentionUncontrolled narrow-angle glaucomaHypersensitivity to oxybutynin or any component
| Precautions | Angioedema (rare but serious hypersensitivity reaction), Urinary retention (may precipitate in patients with bladder outlet obstruction), Gastrointestinal obstructive disorders (risk of delayed gastric emptying), Controlled narrow-angle glaucoma (may exacerbate), Central nervous system effects (e.g., somnolence, dizziness; caution with activity requiring alertness), Dermatitis at application site |
| Food/Dietary | No specific food interactions. Alcohol may increase anticholinergic effects such as drowsiness or dizziness; limit or avoid alcohol consumption. Stay hydrated to minimize dry mouth. |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | GELNIQUE 3% (oxybutynin topical gel) is classified as Pregnancy Category B. Animal studies have not demonstrated fetal risk, but there are no adequate and well-controlled studies in pregnant women. Oxybutynin crosses the placenta. First trimester: No known teratogenic effects, but data limited. Second and third trimesters: Potential for anticholinergic effects on fetal heart rate and gastrointestinal motility; use only if clearly needed. |
| Fetal Monitoring | Monitor maternal heart rate and blood pressure due to anticholinergic effects. Fetal monitoring: Consider non-stress test or biophysical profile if prolonged use in third trimester. Assess for maternal urinary retention, constipation, and heat intolerance (reduced sweating). |
| Fertility Effects | Oxybutynin may affect male and female fertility due to anticholinergic effects on sexual function (e.g., erectile dysfunction, decreased libido). Animal studies show no direct impairment of fertility, but clinical significance in humans is uncertain. Reversible upon discontinuation. |
| Clinical Pearls | Apply gel to clean, dry, intact skin on abdomen, upper thighs, or upper arms. Rotate application sites daily. Avoid showering or swimming for at least 1 hour after application. Do not wash application site for at least 1 hour. Use sunscreen if exposed to sun; oxybutynin gel may cause photosensitivity. Monitor for anticholinergic effects (dry mouth, constipation, blurred vision, urinary retention). Patients with narrow-angle glaucoma or GI obstructive disorders should avoid use. If a transdermal patch is being replaced, remove the patch before applying the gel. Dose is 3 mL (84 mg) applied once daily. |
| Patient Advice | Apply the gel at the same time each day to clean, dry, intact skin. · Rotate application sites among abdomen, upper thighs, and upper arms to avoid skin irritation. · Do not shower, bathe, or swim for at least 1 hour after applying the gel. · Wash hands immediately after applying the gel. · Avoid exposing the application area to direct sunlight, and use sunscreen if necessary. · Tell your doctor if you have a history of glaucoma, urinary retention, or gastrointestinal problems. · Drink plenty of fluids to help prevent dry mouth and constipation. · Do not drink alcohol while using this medication; it may increase drowsiness or dizziness. |